Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a confirmed diagnosis of Waldenström macroglobulinemia (WM) or lymphoplasmacytic lymphoma (LPL), based on recognised international medical classification systems.
- People who have already received at least one standard treatment for WM or LPL.
- People whose disease is measurable, meaning either a specific protein called IgM is detected at a high enough level in the blood, or tumour spots of a certain size are visible on a scan (confirm with trial site for exact measurements that apply to each situation).
- People whose doctor has determined that whole-body cancer treatment is needed for their WM or LPL.
- People who are reasonably active and able to carry out daily activities, as assessed using a standard medical scale (confirm with trial site).
- People whose liver, kidneys, and bone marrow are functioning well enough to meet the trial's requirements (confirm with trial site for specific thresholds).
Who may not be able to join:
- People who have previously been treated with a drug called venetoclax or any other therapy that targets the same protein (BCL-2).
- People who have an active infection that is not under control.
- People who have a known bleeding disorder, such as von Willebrand's disease or haemophilia.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants with Major Response; Number of Participants with Major Response in participants with IgM >= 500 mg/dL
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.